Mycobacterium susceptibility to ivermectin by inhibition of eccD3, an ESX-3 secretion system component.
Fig 7
Growth curve of M. smegmatis PLJR962-eccD3-gRNA strain with ivermectin.
Growth curves of M. smegmatis mc2 155 wild type strain (diamonds, inner graph (a) and (c), M. smegmatis PLJR962-eccD3-gRNA strain (circles) (a) and (b), and M. smegmatis PLJR962-control-gRNA strain (triangles) (c) and (d) without ATc (gray line) and with ATc (black line) 0.0002 μM (100 ng/mL), and with a final concentration of ivermectin of 0.062 μM 64 μg/mL) (a) and (c) and 0.031 μM (32 μg/mL) (b) and (d), and 0.03 μM (20 μg/mL) of kanamycin. In the two ivermectin concentrations tested in M. smegmatis PLJR962-eccD3-gRNA strain, a significant difference was observed among treatments with and without ATc from 20 to 27 hours. An unpaired two-tailed Student’s t-test was used and p < 0.001 (***) and p <0.05 (*) were obtained (S7 Table and MDdb Science Gateway at http://md-db.org with entry ID 690005 in-vitro data). M. smegmatis mc2 155 wild type growth curve were included in the inner graph. Each assay was performed with technical triplicates showing the average data with the standard deviation as error bars.